📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines (2021)

First Author: Monin-Aldama L

Attributed to: Evaluation of the CD4+ T cell tumour microenvironment of low grade B cell lymphoproliferative disorders funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2021.03.17.21253131

Publication URI: http://dx.doi.org/10.1101/2021.03.17.21253131

Type: Preprint